1. Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. (9th January 2019) Authors: Soria, J -C; Cortes, J; Massard, C; Armand, J -P; De Andreis, D; Ropert, S; Lopez, E; Catteau, A; James, J; Marier, J -F; Beliveau, M; Martell, R E; Baselga, J Journal: Annals of oncology Issue: Volume 30:Number 6(2019) Page Start: 1020 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗